Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) just unveiled an update.
Lepu Biopharma Co., Ltd. successfully conducted its first extraordinary general meeting for 2025, presided over by chairman Dr. Pu Zhongjie. During this meeting, all proposed resolutions, including the approval of a framework agreement with Lepu Medical Technology for CDMO services and the appointment of Ernst & Young as auditors, were passed with overwhelming shareholder support. These developments signify a strategic collaboration and financial oversight enhancement, potentially strengthening the company’s operational capabilities and market positioning.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. is a joint stock company incorporated in the People’s Republic of China. It operates in the biopharmaceutical industry, focusing on developing innovative medical treatments and technologies. The company collaborates with entities like Lepu Medical Technology to enhance its service offerings, targeting a diverse market within the healthcare sector.
YTD Price Performance: -4.20%
Average Trading Volume: 5,642,659
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$4.29B
For detailed information about 2157 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue